Anti-L1CAM antibody therapy for rare diseases
Persone
(Responsabile)
Abstract
development of therapeutic antibodies and IOR's expertise in basic and translational research in rare cancer types, we aim to develop a new efficacious immunotherapy for patients suffering from highly aggressive malignancies.
Informazioni aggiuntive
Data d'inizio
01.11.2020
Data di fine
01.11.2022
Durata
24 Mesi
Enti finanziatori
Stato
Concluso
Categoria
Innosuisse /
Innovation projects
